At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BCTX BriaCell Therapeutics Corp.
Post-Market Trading 03-24 16:59:32 EDT
4.46
-0.01
-0.22%
High4.78
Low4.41
Vol36.03K
Open4.50
D1 Closing4.47
Amplitude8.30%
Mkt Cap16.54M
Tradable Cap11.14M
Total Shares3.71M
T/O165.51K
T/O Rate1.44%
Tradable Shares2.50M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
BriaCell Therapeutics Says Data Safety Monitoring Board Recommends Continuation of Phase 3 Trial in Metastatic Breast Cancer
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.